Research graph
References from Factors associated with patient preferences for statin therapy in primary prevention. Local targets link to admitted publications; unresolved targets remain external evidence.
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
10.1016/s0140-6736(12)60367-5 · 2012 · External reference
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials
10.1016/s0140-6736(14)61368-4 · 2015 · External reference
Interpretation of the evidence for the efficacy and safety of statin therapy
10.1016/s0140-6736(16)31357-5 · 2016 · External reference
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the american college of cardiology/american heart association task force on clinical practice guidelines
2019 · External reference
Measuring public preferences for statin therapy using the smallest worthwhile difference
10.1001/jamainternmed.2025.7958 · 2026 · External reference
A critical review of methods used to determine the smallest worthwhile effect of interventions for low back pain
10.1016/j.jclinepi.2011.06.018 · 2012 · External reference
Patient-perceived versus actual risk of cardiovascular disease and associated willingness to consider and use prevention therapy
10.1161/circoutcomes.120.006548 · 2021 · External reference
Patient-reported adherence to statin therapy, barriers to adherence, and perceptions of cardiovascular risk
10.1371/journal.pone.0191817 · 2018 · External reference
Low health literacy and health outcomes: an updated systematic review
10.7326/0003-4819-155-2-201107190-00005 · 2011 · External reference
A systematic review uncovering modifiable influences on Statin adherence
10.2147/ppa.s502645 · 2025 · External reference
Data quality in online human-subjects research: comparisons between MTurk, Prolific, CloudResearch, Qualtrics, and SONA
10.1371/journal.pone.0279720 · 2023 · External reference
Increased awareness and decreased acceptance of genome-editing technology: the impact of the Chinese twin babies
10.1371/journal.pone.0238128 · 2020 · External reference
Japanese health and safety information for overseas visitors: protocol for a randomized controlled trial
10.1186/s12889-021-10627-w · 2021 · External reference
Sufficiently important difference: expanding the framework of clinical significance
10.1177/0272989x05276863 · 2005 · External reference
Japan Atherosclerosis Society (JAS) Guidelines for Prevention of atherosclerotic cardiovascular Diseases 2022
10.5551/jat.gl2022 · 2024 · External reference
The Table 2 fallacy: presenting and interpreting confounder and modifier coefficients
10.1093/aje/kws412 · 2013 · External reference
Unresolved reference
External reference
Minimal clinically important difference: defining what really matters to patients
10.1001/jama.2014.13128 · 2014 · External reference
Minimal important change (MIC): a conceptual clarification and systematic review of MIC estimates of PROMIS measures
10.1007/s11136-021-02925-y · 2021 · External reference
Measuring clinical importance in a trial of interventions for mixed urinary incontinence
10.1001/jama.2019.19730 · 2020 · External reference
The smallest worthwhile effect of nonsteroidal anti-inflammatory drugs and physiotherapy for chronic low back pain: a benefit-harm trade-off study
10.1016/j.jclinepi.2013.02.018 · 2013 · External reference
Smallest worthwhile effect of land-based and water-based pulmonary rehabilitation for COPD
10.1183/23120541.00007-2015 · 2015 · External reference
Estimating the smallest worthwhile difference of recommended psychotherapies for depression: observational study
10.1192/bjp.2025.10453 · 2025 · External reference
Determining the smallest worthwhile difference of beta-3 agonist treatment for overactive bladder: a benefit-harm trade-off study
10.1007/s00345-026-06274-8 · 2026 · External reference
Statins for primary prevention-the gap between guidelines and patient preferences
10.1001/jamainternmed.2025.7955 · 2026 · External reference
Prevalence and determinants of adherence to Statin therapy: a systematic review and meta-analysis
10.1093/eurjpc/zwaf769 · 2025 · External reference
Cardiovascular predicted risk: a population-based comparison of the pooled cohorts equation and PREVENT
10.1016/j.ijcard.2024.132423 · 2024 · External reference
Patient preference distribution for use of Statin Therapy
10.1001/jamanetworkopen.2021.0661 · 2021 · External reference
Predictors of informed people's preferences for Statin therapy to reduce cardiovascular disease risk: an internet survey study
10.1007/s11606-022-07440-5 · 2023 · External reference
Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials
10.1016/s0140-6736(25)01578-8 · 2026 · External reference
Perceptions and knowledge of cholesterol and lipid-lowering medications among treatment-naive individuals: a cross-sectional study
10.2147/ppa.s511454 · 2025 · External reference
Providing additional information about the benefits of statins in a leaflet for patients with coronary heart disease: a qualitative study of the impact on attitudes and beliefs
10.1136/bmjopen-2016-012000 · 2016 · External reference
Effects of communitywide education on cardiovascular disease risk factors. The Stanford Five-City Project
10.1001/jama.1990.03450030083037 · 1990 · External reference
Japanese National plan for promotion of measures against cerebrovascular and cardiovascular disease
10.1161/circulationaha.120.052737 · 2021 · External reference
Trends and disparities in treatment and control of atherosclerotic cardiovascular disease in US adults, 1999 to 2018
10.1161/jaha.123.032527 · 2024 · External reference
